AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10830459 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced system
Number of subjects: 0
Study 10830459 — intervention group
Group type: COMPARATOR
Intervention: Standard bottle
Number of subjects: 0
Study 10830459 — intervention group
Group type: COMPARATOR
Intervention: Test bottle
Number of subjects: 0
Study 10830459 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-free bottle
Number of subjects: 0
Study 2349253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-base 10 mg
Number of subjects: 5
Study 2349253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-base 20 mg
Number of subjects: 5
Study 2349253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-base 40 mg
Number of subjects: 5
Study 106428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclazindol 50 mg orally
Number of subjects: 15
Study 106428 — intervention group
Group type: COMPARATOR
Intervention: Tandamine
Number of subjects: 15
Study 106428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclazindol
Number of subjects: 15
Study 30506893 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular fractional area change
Number of subjects: 283
Study 30506893 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular indexed end-diastolic volume
Number of subjects: 283
Study 30506893 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular indexed end-systolic volume
Number of subjects: 283
Study 30506893 — intervention group
Group type: EXPERIMENTAL
Intervention: RV ejection fraction increase
Number of subjects: 283
Study 29084796 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives conditional on attending scheduled pregnancy follow‐up consultations
Number of subjects: 2000
Study 29084796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 2000
Study 25366969 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose budesonide/formoterol (HDBF) 640/18 μg
Number of subjects: 120
Study 25366969 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (BFMRT)
Number of subjects: 120
Study 25366969 — intervention group
Group type: COMPARATOR
Intervention: Control group (terbutaline 1 mg)
Number of subjects: 120
Study 25366969 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower dose budesonide/formoterol)
Number of subjects: 120
Study 24398815 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised treatment group
Number of subjects: 32
Study 24398815 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 23025249 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation (R&R) program
Number of subjects: 84
Study 23025249 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation (R&R) program (completers)
Number of subjects: 84
Study 23025249 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 84
Study 18945254 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 300 microg
Number of subjects: 166
Study 18945254 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 100 microg
Number of subjects: 166
Study 18945254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 18945254 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 (both doses)
Number of subjects: 166
Study 18945254 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010
Number of subjects: 166
Study 17763150 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment (81, 162 and 325 mg/day for 4 weeks each)
Number of subjects: 110
Study 16172177 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled intervention, average trial size of 32 subjects at 5 dose levels.
Number of subjects: 3323
Study 16172177 — intervention group
Group type: COMPARATOR
Intervention: Crossover designs (more frequent in early publications) and parallel single-dose designs.
Number of subjects: 3323
Study 12473551 — intervention group
Group type: EXPERIMENTAL
Intervention: S-nitrosoglutathione (GSNO)
Number of subjects: 16
Study 12473551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9872244 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal screening
Number of subjects: 53781
Study 7699439 — intervention group
Group type: EXPERIMENTAL
Intervention: Indium-111-pentetreotide
Number of subjects: 47
Study 7699439 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging methods
Number of subjects: 47
Study 2642633 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (n = 13)
Number of subjects: 24
Study 2642633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 24
Study 7383476 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% econazole vaginal cream, used once daily at bedtime for 7 days
Number of subjects: 178
Study 7383476 — intervention group
Group type: COMPARATOR
Intervention: 100‐mg clotrimazole vaginal tablets, used once daily at bedtime for 7 days
Number of subjects: 178
Study 7383476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 178
Study 30859941 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg amphetamine sulfate
Number of subjects: 18
Study 30859941 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg amphetamine sulfate
Number of subjects: 18
Study 30859941 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg amphetamine sulfate
Number of subjects: 18
Study 30859941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29061602 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training via an online probe detection task with images of faces displaying neutral and disgusted expressions
Number of subjects: 31
Study 29061602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 31
Study 26018054 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional trocar wound infiltration with bupivacaine (group B)
Number of subjects: 0
Study 26018054 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional trocar wound infiltration and intraperitoneal instillation of bupivacaine (group C)
Number of subjects: 0
Study 26018054 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 0
Study 25085960 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1800
Study 25085960 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary revascularization with drug-eluting stents (DES-PCI)
Number of subjects: 1800
Study 25085960 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 25085960 — intervention group
Group type: COMPARATOR
Intervention: DES-PCI
Number of subjects: 1800
Study 22520932 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide (V/HCTZ) 160/12.5 mg
Number of subjects: 301
Study 22520932 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 301
Study 22520932 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (V) 160 mg
Number of subjects: 301
Study 20170329 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on adherence during review consultations
Number of subjects: 26
Study 20170329 — intervention group
Group type: COMPARATOR
Intervention: Undisclosed adherence to parents and treating physician
Number of subjects: 26
Study 18063452 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard volume of local anaesthetic containing 2% lidocaine and 1/80,000 adrenaline
Number of subjects: 45
Study 18063452 — intervention group
Group type: COMPARATOR
Intervention: Double the standard volume with 1% lidocaine and 1/160,000 adrenaline
Number of subjects: 45
Study 16110841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid perfusion in healthy volunteers
Number of subjects: 3
Study 16110841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid exposure in healthy epithelium
Number of subjects: 3
Study 16110841 — intervention group
Group type: COMPARATOR
Intervention: Acid exposure in GERD patients
Number of subjects: 3
Study 11818921 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable straight‐shaft spiked forceps
Number of subjects: 75
Study 11818921 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable angled‐shaft spiked forceps
Number of subjects: 75
Study 11818921 — intervention group
Group type: COMPARATOR
Intervention: Disposable lateral cup forceps
Number of subjects: 75
Study 10424505 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA cromolyn sodium (2 mg, two inhalations, qid for 12 weeks)
Number of subjects: 280
Study 10424505 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC cromolyn sodium (2 mg, two inhalations, qid for 12 weeks)
Number of subjects: 280
Study 10424505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 2324880 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic scale (SMART; Olympic Medical)
Number of subjects: 50
Study 2324880 — intervention group
Group type: COMPARATOR
Intervention: Mechanical scale (Toledo)
Number of subjects: 50
Study 6114524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 23
Study 6114524 — intervention group
Group type: COMPARATOR
Intervention: DSCG
Number of subjects: 23
Study 30547261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 45
Study 30547261 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercises
Number of subjects: 45
Study 30547261 — intervention group
Group type: COMPARATOR
Intervention: Routine cardiac rehabilitation programme (Control)
Number of subjects: 45
Study 28236769 — intervention group
Group type: COMPARATOR
Intervention: ECRF group
Number of subjects: 2686
Study 28236769 — intervention group
Group type: COMPARATOR
Intervention: RIEC group
Number of subjects: 2686
Study 26408562 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management (drainage)
Number of subjects: 3444
Study 26408562 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management (medical)
Number of subjects: 3444
Study 26408562 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 3444
Study 23916919 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-delivered intervention
Number of subjects: 489
Study 23916919 — intervention group
Group type: COMPARATOR
Intervention: Web-based intervention
Number of subjects: 489
Study 23916919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (counselor-delivered and web-based)
Number of subjects: 489
Study 21478216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (400 mg b.i.d.)
Number of subjects: 324
Study 21478216 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 324
Study 19583518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for ASB
Number of subjects: 105
Study 19583518 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment only for symptomatic infections
Number of subjects: 105
Study 19583518 — intervention group
Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 105
Study 17889086 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of iron daily in the second half of pregnancy
Number of subjects: 0
Study 17889086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 0
Study 15173273 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid (via a 15-minute infusion every 3 weeks for 15 months)
Number of subjects: 122
Study 15173273 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 122
Study 15173273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 11294919 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 3,600 mg daily for 9 months
Number of subjects: 204
Study 11294919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 9466166 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-8359
Number of subjects: 0
Study 9466166 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 9466166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7930332 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician assessment before psychiatrist's opinion
Number of subjects: 2100
Study 7930332 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician assessment after psychiatrist's opinion
Number of subjects: 2100
Study 7930332 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of the correct standard for competence
Number of subjects: 2100
Study 7930332 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses regarding conditions establishing incompetence
Number of subjects: 2100
Study 7930332 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance comparison between psychiatrists and other physicians
Number of subjects: 2100
Study 3410944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile skin preparation technique
Number of subjects: 71
Study 3410944 — intervention group
Group type: COMPARATOR
Intervention: Clean technique
Number of subjects: 71
Study 3410944 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 71
Study 3410944 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic application in patients with poor hygiene
Number of subjects: 71
Study 31944617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 549
Study 31944617 — intervention group
Group type: COMPARATOR
Intervention: Comparison program
Number of subjects: 549
Study 29738561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) amoxicillin/clavulanate 1750 mg IR twice a day (Period 2)
Number of subjects: 315
Study 29738561 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) amoxicillin/clavulanate 875/125 mg IR
Number of subjects: 315
Study 29738561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) amoxicillin/clavulanate 2000 mg ER (Period 1)
Number of subjects: 315
Study 29738561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) amoxicillin/clavulanate
Number of subjects: 315
Study 29738561 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) amoxicillin/clavulanate
Number of subjects: 315
Study 26789984 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve (EBV) therapy
Number of subjects: 492
Study 26789984 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 492
Study 26215478 — intervention group
Group type: EXPERIMENTAL
Intervention: ASK intervention model (300 min/week of physical activity/PE)
Number of subjects: 1145
Study 26215478 — intervention group
Group type: COMPARATOR
Intervention: Curriculum-prescribed physical activity intervention (135 min/week)
Number of subjects: 1145
Study 23979267 — intervention group
Group type: EXPERIMENTAL
Intervention: modified whole blood (mWB)
Number of subjects: 107
Study 23979267 — intervention group
Group type: COMPARATOR
Intervention: component therapy (COMP)
Number of subjects: 107
Study 21092076 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/carboplatin (DC)
Number of subjects: 0
Study 21092076 — intervention group
Group type: COMPARATOR
Intervention: docetaxel single-agent (D)
Number of subjects: 0
Study 19138237 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroid withdrawal for 12 weeks
Number of subjects: 27
Study 19138237 — intervention group
Group type: COMPARATOR
Intervention: Inhaled steroid treatment (before withdrawal)
Number of subjects: 27
Study 16103032 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute care including a 24 hour crisis resolution team
Number of subjects: 260
Study 16103032 — intervention group
Group type: COMPARATOR
Intervention: Standard care from inpatient services and community mental health teams
Number of subjects: 260
Study 12113325 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL 25% sucrose given orally 2 min before heel prick
Number of subjects: 12
Study 12113325 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intake by nasogastric tube once during the last hour before heel prick
Number of subjects: 12
Study 12113325 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intake by nasogastric tube and 1 mL 25% sucrose given orally 2 min before heel prick
Number of subjects: 12
Study 12113325 — intervention group
Group type: COMPARATOR
Intervention: Sterilized water
Number of subjects: 12
Study 10344466 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fiber (PMX-F) treatment
Number of subjects: 30
Study 10344466 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 30
Study 8964127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 105
Study 8964127 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme gene polymorphism
Number of subjects: 105
Study 1749827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral scopolamine (1.2 mg)
Number of subjects: 0
Study 1749827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 0
Study 6762044 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir (ACV) eye ointment
Number of subjects: 38
Study 6762044 — intervention group
Group type: COMPARATOR
Intervention: 0.5% idoxiuridine (IDU)
Number of subjects: 38
Study 30965064 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Number of subjects: 744
Study 30965064 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 744
Study 29795005 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCS-sweetened beverage
Number of subjects: 41
Study 29795005 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (artificially sweetened)
Number of subjects: 41
Study 26844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for 12 months or longer
Number of subjects: 323
Study 26844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 323
Study 26844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of breastfeeding
Number of subjects: 323
Study 26844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 323
Study 24768443 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection (AD)
Number of subjects: 238
Study 24768443 — intervention group
Group type: COMPARATOR
Intervention: No axillary dissection (no AD)
Number of subjects: 238
Study 24768443 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery with postoperative radiotherapy and tamoxifen for five years
Number of subjects: 238
Study 22383085 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (bolus of 0.5 mg·kg(‐1) iv at induction followed by infusion of 5‐15 μg·kg(‐1)·min(‐1))
Number of subjects: 60
Study 22383085 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil plus ketamine (bolus of ketamine 0.5 mg·kg(‐1) iv and remifentanil 0.5 μg·kg(‐1) iv at induction followed by a remifentanil infusion titrated over a range of 0.1‐0.5 μg·kg(‐1)·min(‐1))
Number of subjects: 60
Study 22383085 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60
Study 22383085 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil plus ketamine
Number of subjects: 60
Study 19403955 — intervention group
Group type: EXPERIMENTAL
Intervention: CCP (6 g/d CLA + 9 g/d C + 36 g/d P)
Number of subjects: 69
Study 19403955 — intervention group
Group type: COMPARATOR
Intervention: CP (C + P + placebo oil)
Number of subjects: 69
Study 19403955 — intervention group
Group type: COMPARATOR
Intervention: P (P + placebo oil)
Number of subjects: 69
Study 19403955 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 69
Study 16426124 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (100 mg/daily) plus aescin (80 mg/daily)
Number of subjects: 96
Study 16426124 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (100 mg/daily) plus aescin (80 mg/daily) plus tamsulosin (0.4 mg/daily)
Number of subjects: 96
Study 12569556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal IgA response
Number of subjects: 627
Study 12569556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal IgG response
Number of subjects: 627
Study 12569556 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA response
Number of subjects: 627
Study 12569556 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG response
Number of subjects: 627
Study 10976549 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 21
Study 10976549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8787684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 125 mg/m2
Number of subjects: 24
Study 8787684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 250 mg/m2
Number of subjects: 24
Study 8787684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 500 mg/m2
Number of subjects: 24
Study 8787684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 1000 mg/m2
Number of subjects: 24
Study 1485740 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy and pharmacologic therapy for 12 patients
Number of subjects: 33
Study 1485740 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic therapy alone for 21 patients
Number of subjects: 33
Study 6507339 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet providing 20% of energy from protein
Number of subjects: 12
Study 6507339 — intervention group
Group type: COMPARATOR
Intervention: Diet providing 10% of energy from protein
Number of subjects: 12
Study 30762310 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-off crosslinking (CXL) procedure
Number of subjects: 60
Study 30762310 — intervention group
Group type: EXPERIMENTAL
Intervention: Iatrogenic corneal injury model in rabbits
Number of subjects: 60
Study 28682186 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promotion intervention targeting physical activity and dietary habits (fruit, vegetable, and fat consumption)
Number of subjects: 176
Study 28682186 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-promotion intervention
Number of subjects: 176
Study 27458945 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS alone
Number of subjects: 213